UniProtKB/Swiss-Prot A0AV02: Variant p.Ile281Val

Solute carrier family 12 member 8
Gene: SLC12A8
Feedback?

Variant information Variant position:

281 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Isoleucine (I) to Valine (V) at position 281 (I281V, p.Ile281Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs621383 [ dbSNP | Ensembl ]

Sequence information Variant position:

281 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

714 The length of the canonical sequence.
Location on the sequence:

AASIPLGSLAAVGISWFLYI I FVFLLGAICTREALRYDFLI The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         AAS----IPLGSLAAVGISWFLYIIFVFLLGAICTREALRYDFLI

Mouse                         ADS----VPLGSLAAVGVSWFLYIIFAFLLGAVCTREALRS

Rat                           ADQHTPRLPSSCWVSRG---FSNIIFAFLLGAVCTREALRS

Xenopus laevis                SIN----IPLGSLAAIGTSWFLYVVFVFLLGAICTREFLRY

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 714	Solute carrier family 12 member 8
Transmembrane	266 – 289	Helical
Alternative sequence	1 – 406	Missing. In isoform 5.

Literature citations
Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map.
Hewett D.; Samuelsson L.; Polding J.; Enlund F.; Smart D.; Cantone K.; See C.G.; Chadha S.; Inerot A.; Enerback C.; Montgomery D.; Christodolou C.; Robinson P.; Matthews P.; Plumpton M.; Wahlstrom J.; Swanbeck G.; Martinsson T.; Roses A.; Riley J.; Purvis I.;
Genomics 79:305-314(2002)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); SUSCEPTIBILITY TO PSORIASIS; FUNCTION; TISSUE SPECIFICITY; VARIANTS CYS-181 AND VAL-281; Characterization of Homo sapiens CCC9, a novel member of the cation-chloride cotransporter gene family.
Mount D.B.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANTS VAL-281 AND GLN-664; The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4); VARIANT VAL-281;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.